New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
12:41 EDTQGENQIAGEN reaffirms FY12 EPS view $1.04-1.06, consensus $1.00
Sees revenue up approximately 8-9% CER on a mix of contributions from the acquisitions of Cellestis and Ipsogen in 2011 and AmniSure in May 2012, as well as growth in the rest of the business. Full-year reported sales are expected to be adversely affected by currency movements against the U.S. dollar, QIAGEN's reporting currency.This guidance takes into account approximately half a cent of dilution expected on adjusted EPS results in the fourth quarter of 2012 from the combined effect of the share repurchase program as well as higher interest expenses incurred through the U.S. private placement. These expectations do not take into account any further acquisitions that could be completed in 2012.
News For QGEN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
06:21 EDTQGENQIAGEN downgraded to Sell from Neutral at Goldman
Goldman downgraded QIAGEN to Sell based on a mixed growth outlook for new products and the dilutive impact on the core franchise value from M&A. Price target lowered to $19 from $21.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use